Nat Commun:NOD2的缺乏促进克罗恩病分泌型IgA复合物的逆向转运

2021-01-20 xiaozeng MedSci原创

宿主免疫系统区分病原体和共生体的能力对于粘膜稳态的维持是必不可少的。

宿主免疫系统区分病原体和共生体的能力对于粘膜稳态的维持是必不可少的。当存在功能或遗传缺陷时,维持肠道粘膜稳态的相关机制尤为重要。而慢性肠道炎症如克罗恩氏病(CD)的发生发展也与免疫反应精细平衡的紊乱相关。

CD是一种特发性的慢性区域性肠炎,通常会影响回肠末端,但也可能影响从口腔到肛门的胃肠道中的任何部分。CD一般被认为是由具有特定遗传背景的个体中共生细菌的自我识别能力下降和粘膜屏障功能障碍所引起的。

在CD患者中NOD2突变会增加SIgA的反向胞吞作用

分泌型IgA(SIgA)是人类和许多其他哺乳动物粘膜表面上最丰富的免疫球蛋白。SIgA可以通过区分肠道病原体和肠道共生细菌来保护肠道上皮。肠道免疫系统对肠道病原体的识别会诱导高亲和力、T细胞依赖性的病原体特异性IgA的产生。

NOD2缺乏增加了体内IgA的逆向转运

肠道微皱折细胞(M细胞)主要负责将SIgA-病原体复合物转运到肠道相关淋巴组织中。SIgA/共生复合物的摄取对于启动粘膜的适应性免疫至关重要。

CD患者的SIgA-病原体复合物在M细胞中的逆向运输增加

该研究旨在探究在克罗恩病(CD)中SIgA逆向转运免疫复合物的作用。研究人员发现,与无NOD2突变的CD患者以及健康个体相比,携带NOD2突变的CD患者的SIgA转运显著增加。NOD2通过下调参与逆行运输的两个受体Dectin-1和Siglec-5的表达水平,以影响M细胞的IgA运输。


总而言之,以上的研究结果揭示了NOD2介导的对肠道菌群的粘膜反应的调节机制,该机制引起了克罗恩病患者的肠道炎症和营养不良


原始出处:

Rochereau, N., Roblin, X., Michaud, E. et al. NOD2 deficiency increases retrograde transport of secretory IgA complexes in Crohn’s disease. Nat Commun 12, 261 (11 January 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087883, encodeId=60b6208e883f3, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 27 10:58:02 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696364, encodeId=fd991696364f9, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sun Nov 21 21:58:02 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884913, encodeId=c9a7188491351, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 21 09:58:02 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682650, encodeId=7421168265011, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 14 08:58:02 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910662, encodeId=6b981910662eb, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Feb 03 04:58:02 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503960, encodeId=f955150396047, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539021, encodeId=64ba15390210a, content=<a href='/topic/show?id=70381291298' target=_blank style='color:#2F92EE;'>#NOD2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12912, encryptionId=70381291298, topicName=NOD2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ba613095346, createdName=mxj1971616, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=)]
    2021-06-27 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087883, encodeId=60b6208e883f3, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 27 10:58:02 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696364, encodeId=fd991696364f9, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sun Nov 21 21:58:02 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884913, encodeId=c9a7188491351, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 21 09:58:02 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682650, encodeId=7421168265011, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 14 08:58:02 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910662, encodeId=6b981910662eb, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Feb 03 04:58:02 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503960, encodeId=f955150396047, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539021, encodeId=64ba15390210a, content=<a href='/topic/show?id=70381291298' target=_blank style='color:#2F92EE;'>#NOD2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12912, encryptionId=70381291298, topicName=NOD2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ba613095346, createdName=mxj1971616, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=)]
    2021-11-21 yzh409
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087883, encodeId=60b6208e883f3, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 27 10:58:02 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696364, encodeId=fd991696364f9, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sun Nov 21 21:58:02 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884913, encodeId=c9a7188491351, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 21 09:58:02 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682650, encodeId=7421168265011, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 14 08:58:02 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910662, encodeId=6b981910662eb, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Feb 03 04:58:02 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503960, encodeId=f955150396047, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539021, encodeId=64ba15390210a, content=<a href='/topic/show?id=70381291298' target=_blank style='color:#2F92EE;'>#NOD2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12912, encryptionId=70381291298, topicName=NOD2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ba613095346, createdName=mxj1971616, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=)]
    2021-02-21 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087883, encodeId=60b6208e883f3, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 27 10:58:02 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696364, encodeId=fd991696364f9, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sun Nov 21 21:58:02 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884913, encodeId=c9a7188491351, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 21 09:58:02 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682650, encodeId=7421168265011, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 14 08:58:02 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910662, encodeId=6b981910662eb, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Feb 03 04:58:02 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503960, encodeId=f955150396047, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539021, encodeId=64ba15390210a, content=<a href='/topic/show?id=70381291298' target=_blank style='color:#2F92EE;'>#NOD2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12912, encryptionId=70381291298, topicName=NOD2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ba613095346, createdName=mxj1971616, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087883, encodeId=60b6208e883f3, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 27 10:58:02 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696364, encodeId=fd991696364f9, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sun Nov 21 21:58:02 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884913, encodeId=c9a7188491351, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 21 09:58:02 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682650, encodeId=7421168265011, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 14 08:58:02 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910662, encodeId=6b981910662eb, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Feb 03 04:58:02 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503960, encodeId=f955150396047, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539021, encodeId=64ba15390210a, content=<a href='/topic/show?id=70381291298' target=_blank style='color:#2F92EE;'>#NOD2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12912, encryptionId=70381291298, topicName=NOD2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ba613095346, createdName=mxj1971616, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2087883, encodeId=60b6208e883f3, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 27 10:58:02 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696364, encodeId=fd991696364f9, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sun Nov 21 21:58:02 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884913, encodeId=c9a7188491351, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 21 09:58:02 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682650, encodeId=7421168265011, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 14 08:58:02 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910662, encodeId=6b981910662eb, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Feb 03 04:58:02 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503960, encodeId=f955150396047, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539021, encodeId=64ba15390210a, content=<a href='/topic/show?id=70381291298' target=_blank style='color:#2F92EE;'>#NOD2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12912, encryptionId=70381291298, topicName=NOD2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ba613095346, createdName=mxj1971616, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2087883, encodeId=60b6208e883f3, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Jun 27 10:58:02 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696364, encodeId=fd991696364f9, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Sun Nov 21 21:58:02 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884913, encodeId=c9a7188491351, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 21 09:58:02 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682650, encodeId=7421168265011, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 14 08:58:02 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910662, encodeId=6b981910662eb, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Wed Feb 03 04:58:02 CST 2021, time=2021-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503960, encodeId=f955150396047, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539021, encodeId=64ba15390210a, content=<a href='/topic/show?id=70381291298' target=_blank style='color:#2F92EE;'>#NOD2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12912, encryptionId=70381291298, topicName=NOD2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ba613095346, createdName=mxj1971616, createdTime=Fri Jan 22 13:58:02 CST 2021, time=2021-01-22, status=1, ipAttribution=)]
    2021-01-22 mxj1971616

相关资讯

TAG: 英夫利昔单抗治疗对回肠结肠克罗恩病患者不同肠段黏膜愈合的作用差异

克罗恩病(CD)是一种慢性复发性炎症性肠病(IBD),经常导致患者出现狭窄,脓肿或瘘管等疾病并发症。

Clin Gastroenterology H:缩短乌司奴单抗的用药时间能够提高治疗克罗恩病的有效性

虽然目前乌司奴单抗已经被指南推荐作为二线的治疗克罗恩病的生物制剂,但是仍有部分患者对于乌司奴单抗存在失应答的现象。

AP&T: 长期使用维多珠单抗治疗的有效性和安全性是怎么样的?

溃疡性结肠炎(UC)和克罗恩氏病(CD)是慢性炎症性肠病,这类疾病的特征是血性腹泻,腹痛以及大便急迫和大小便失禁。诱导中度至重度活动的UC和CD缓解的常规治疗。

TAG:血小板与淋巴细胞百分比比指数是一种监测克罗恩病内镜活动度的简单非侵入性工具

克罗恩病(CD)是一种慢性胃肠道炎症性疾病,其特征是复发和缓解反复交替。 大约一半的CD患者出现肠并发症,例如狭窄或瘘管。因此,在CD的整个疾病过程中,密切监

AJG:疾病病变的位置而非严重程度会影响克罗恩病的内镜缓解率

目前,我们对抗肿瘤坏死因子治疗克罗恩病(CD)患者内镜溃疡的效果以及疾病病变位置对与内镜下缓解的影响知之甚少。本项研究旨在评估用英夫利昔单抗(IFX)治疗CD患者的内镜下疾病活动情况的影响。

Clin Gastroenterology H: 乌司奴单抗的峰值浓度与克罗恩病患者的内镜和生化缓解相关

2019年欧洲克罗恩病和结肠炎组织指南(European Crohn's Colitis Organization)推荐乌司奴单抗可作为中重度克罗恩病治疗的一线生物制剂用药。